This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Políticas Médicas

Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.

Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.

ID Título Última Revisión Siguiente Revisión Descripción Acceso
11.003.015 Gene Expression Profile Testing and Circulating Tumor DNA Testing for Predicting Recurrence in Colon Cancer Sep 18, 2024 Sep 20, 2025 Gene expression assays for determining the prognosis of stage ii or iii colon cancer following surgery are... Ver
11.003.016 Genetic Testing for PTEN Hamartoma Tumor Syndrome Mar 08, 2024 Mar 20, 2025 The pten hamartoma tumor syndrome (phts) includes several syndromes with heterogeneous clinical symptoms,... Ver
11.003.017 Genetic Testing for Hereditary Hearing Loss May 12, 2024 May 20, 2025 Hearing loss is a common birth defect. approximately 1 in 500 newborns in developed countries is affected by... Ver
11.003.018 Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss Sep 19, 2024 Sep 20, 2025 Chromosomal microarray testing of fetal tissue may be considered medically necessary for the evaluation of... Ver
11.003.020 Genetic Testing for Lactase Insufficiency Jul 17, 2024 Policy Archived Genetic testing of adults with suspected lactase insufficiency is proposed as an alternative to current... Ver
11.003.021 Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease Apr 20, 2021 Policy Archived Gene expression testing in the evaluation of patients with stable ischemic heart disease is... Ver
11.003.022 Genetic Testing for Li-Fraumeni Syndrome Aug 20, 2024 Aug 20, 2025 Genetic testing for tp53 may be considered medically necessary to confirm a diagnosis of li-fraumeni syndrome... Ver
11.003.023 General Approach to Evaluating the Utility of Genetic Panels Jan 21, 2025 Jan 20, 2026 Genetic panels that use next-generation sequencing or chromosomal microarray analysis, and are classified in... Ver
11.003.025 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies Nov 22, 2024 Nov 20, 2025 Chromosomal microarray analysis may be considered medically necessary as first-line testing in the initial... Ver
11.003.026 Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies Nov 22, 2024 Nov 20, 2025 The use of comprehensive genomic profiling for selecting targeted cancer treatment is considered... Ver
11.003.027 Germline Genetic Testing for Gene Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1) Sep 12, 2024 Sep 20, 2025 Testing for chek2, atm, and bard1 variants in the assessment of breast cancer risk is considered... Ver
11.003.028 Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Dec 05, 2024 Oct 20, 2025 Apc testing genetic testing of the apc gene may be considered medically necessary in the following... Ver
11.003.029 Epithelial Cell Cytology in Breast Cancer Risk Assesment and High-Risk Patient Management (Ductal Lavage and Suction Collection Systems) May 20, 2019 Policy Archived Cytologic analysis of epithelial cells from nipple aspirations as a technique to assess breast cancer risk... Ver
11.003.030 Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2) Feb 10, 2025 Sep 20, 2025 Genetic testing should be performed in a setting that has suitably trained health care providers who can give... Ver
11.003.031 Genetic Testing for Hereditary Hemochromatosis Jul 10, 2024 Policy Archived Genetic testing for human hemochromatosis (hfe) gene variants may be considered medically necessary in an... Ver
11.003.032 Analysis of Human DNA or RNA in Stool Samples as a Technique for Colorectal Cancer Screening Jan 20, 2025 Jan 20, 2026 Dna or rna analysis of stool samples can be considered medically necessary as a screening technique for... Ver
11.003.033 ALISIS DE LOS PATRONES PROTEOMICOS PARA IDENTIFICACION TEMPRA DEL CÁNCER DE OVARIO May 12, 2016 Policy Archived El análisis de patrones proteómicos en el suero como cernimiento y detección de cáncer de ovario no se... Ver
11.003.034 Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Dec 20, 2024 Dec 20, 2025 The following genetic and protein biomarkers for the diagnosis of prostate cancer are... Ver
11.003.035 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Dec 06, 2024 Dec 20, 2025 The use of the 21-gene reverse transcriptase-polymerase chain reaction (rt-pcr) assay (ie, oncotype dx),... Ver
11.003.036 Genetic Testing for Familial Cutaneous Malignant Melanoma Apr 15, 2024 Apr 20, 2025 Genetic testing for genes associated with familial cutaneous malignant melanoma or associated with... Ver

¿Quieres estar al día con temas sobre salud, noticias, consejos, estilo de vida y más?

¡Suscríbete a nuestro blog para que no te pierdas de nada!

Suscribirse al blog

Queremos personalizar los contenidos de acuerdo a tus preferencias

Por favor selecciona una o más categorias para continuar

¡Gracias por tu suscripción!

Recibirás en tu correo información de tu interés.

787-277-6653 787-474-6326